Fulton Breakefield Broenniman LLC Acquires 85 Shares of Danaher Co. (NYSE:DHR)

Fulton Breakefield Broenniman LLC raised its holdings in shares of Danaher Co. (NYSE:DHR) by 0.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 99,755 shares of the conglomerate’s stock after purchasing an additional 85 shares during the quarter. Danaher accounts for approximately 1.6% of Fulton Breakefield Broenniman LLC’s portfolio, making the stock its 19th largest position. Fulton Breakefield Broenniman LLC’s holdings in Danaher were worth $22,899,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Fort Pitt Capital Group LLC increased its stake in Danaher by 3.2% during the 3rd quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after purchasing an additional 7,421 shares in the last quarter. Good Life Advisors LLC bought a new stake in shares of Danaher in the 3rd quarter worth $217,000. ORG Partners LLC grew its stake in shares of Danaher by 1,212.8% in the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after acquiring an additional 2,559 shares in the last quarter. Harvest Portfolios Group Inc. grew its stake in shares of Danaher by 1.2% in the 3rd quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock worth $56,233,000 after acquiring an additional 2,465 shares in the last quarter. Finally, Stifel Financial Corp lifted its position in shares of Danaher by 1.3% during the 3rd quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock worth $235,583,000 after buying an additional 11,216 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR stock opened at $247.77 on Wednesday. Danaher Co. has a 1 year low of $225.42 and a 1 year high of $281.70. The company has a market cap of $178.96 billion, a P/E ratio of 47.29, a PEG ratio of 4.43 and a beta of 0.83. The firm has a 50-day moving average of $235.75 and a 200 day moving average of $253.65. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Wall Street Analysts Forecast Growth

Several research firms have commented on DHR. Stifel Nicolaus lifted their target price on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. UBS Group lowered their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target on the stock in a report on Friday, December 13th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a report on Tuesday. Six equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $285.81.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.